United States · FDA National Drug Code directory
Trijardy XR
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0597-0390_40d8f12b-47be-4a48-be56-9cd025ac63d4
- Product NDC
- 0597-0390
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- empagliflozin, linagliptin, metformin hydrochloride
- Labeler
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Marketing category
- NDA
- Marketing start / end (source format)
- 20200423
- Source listing expiry
- 20271231
Source-listed ingredients
- EMPAGLIFLOZIN — 25 mg/1
- LINAGLIPTIN — 5 mg/1
- METFORMIN HYDROCHLORIDE — 1000 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-13) · 0597-0390-13
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0390-71) · 0597-0390-71
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →